The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients

Molecular portraits of human breast tumours

Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551 · see citing works

A Proportional Hazards Model for the Subdistribution of a Competing Risk

Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290 · see citing works

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Sørlie, T., Perou, C., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M., van de Rijn, M., Jeffrey, S., et al. (2001) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.191367098 · Cited by 11,695 · see citing works

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

(2005) · The Lancet · doi:10.1016/s0140-6736(05)66544-0 · Cited by 7,531 · see citing works

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works

Triple-negative breast cancer: clinical features and patterns of recurrence

Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · see citing works

A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk

Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957 · see citing works

Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study

Carey, L., Perou, C. M., Livasy, C., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S. N., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,810 · see citing works

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892 · see citing works

Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

Nielsen, T. O., Hsu, F. D., Jensen, K. C., Cheang, M. C. U., Karaca, G., Hu, Z., Hernandez‐Boussard, T., Livasy, C., Cowan, D., Dressler, L. G., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,665 · see citing works

The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

Carey, L., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F. A., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,076 · see citing works

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.

Fisher, B., Brown, A., Mamounas, E. P., Wieand, S., Robidoux, A., Margolese, R. G., Cruz, A. B., Fisher, E. R., Wickerham, D. L., Wolmark, N., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2483 · Cited by 1,802 · see citing works

Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

Kuerer, H. M., Newman, L. A., Smith, T. L., Ames, F. C., Hunt, K. K., Dhingra, K., Theriault, R. L., Singh, G., Binkley, S. M., Sneige, N., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.460 · Cited by 1,329 · see citing works

Basal-Like Breast Cancer: A Critical Review

Rakha, E. A., Reis-Filho, J. S., & Ellis, I. O. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1748 · Cited by 1,164 · see citing works

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

Livasy, C., Karaca, G., Nanda, R., Tretiakova, M., Olopade, O. I., Moore, D. T., & Perou, C. M. (2005) · Modern Pathology · doi:10.1038/modpathol.3800528 · Cited by 1,064 · see citing works

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szállási, Z., Li, Q., Birkbak, N. J., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 982 · see citing works

Triple-negative breast cancer: disease entity or title of convenience?

Carey, L., Winer, E. P., Viale, G., Cameron, D., & Gianni, L. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.154 · Cited by 780 · see citing works

Survival Analysis: A Practical Approach.

Smith, P. J., Parmar, M., & David, M. (1996) · Journal of the American Statistical Association · doi:10.2307/2291609 · Cited by 737 · see citing works

Triple-negative breast cancer—current status and future directions

Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U. A., & Harbeck, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp492 · Cited by 682 · see citing works

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

Ardizzoni, A., Boni, L., Tiseo, M., Fossella, F. V., Schiller, J. H., Paesmans, M., Radosavljevic, D., Paccagnella, A., Zatloukal, P., Mazzanti, P., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk196 · Cited by 612 · see citing works

Expression of luminal and basal cytokeratins in human breast carcinoma

El‐Rehim, D. M. A., Pinder, S. E., Paish, C. E., Bell, J., Blamey, R. W., Robertson, J. F. R., Nicholson, R. I., & Ellis, I. O. (2004) · The Journal of Pathology · doi:10.1002/path.1559 · Cited by 594 · see citing works

The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin

Bhattacharyya, A., Ear, U., Koller, B. H., Weichselbaum, R. R., & Bishop, D. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000276200 · Cited by 584 · see citing works

Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome

van de Rijn, M., Perou, C. M., Tibshirani, R. J., Haas, P., Kallioniemi, O., Kononen, J., Torhorst, J. K. H., Sauter, G., Zuber, M., Köchli, O. R., et al. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64476-8 · Cited by 560 · see citing works

Triple-Negative Breast Cancer: Risk Factors to Potential Targets

Schneider, B. P., Winer, E. P., Foulkes, W. D., Garber, J. E., Perou, C. M., Richardson, A. L., Sledge, G. W., & Carey, L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1208 · Cited by 437 · see citing works

The Role of BRCA1 in the Cellular Response to Chemotherapy

Kennedy, R. D., Quinn, J. E., Mullan, P. B., Johnston, P. G., & Harkin, D. P. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh312 · Cited by 429 · see citing works

BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.

Quinn, J. E., Kennedy, R. D., Mullan, P. B., Gilmore, P. M., Carty, M., Johnston, P. G., & Harkin, D. P. (2003) · PubMed · Cited by 400 · see citing works

Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast

Fulford, L. G., Easton, D. F., Reis-Filho, J. S., Sofronis, A., Gillett, C., Lakhani, S. R., & Hanby, A. M. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02453.x · Cited by 351 · see citing works

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

Byrski, T., Huzarski, T., Dent, R. A., Gronwald, J., Zuziak, D., Cybulski, C., Kładny, J., Górski, B., Lubiński, J., & Narod, S. A. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0128-9 · Cited by 339 · see citing works

Cancer Stem Cells Contribute to Cisplatin Resistance in Brca1/p53 –Mediated Mouse Mammary Tumors

Shafee, N., Smith, C. R., Wei, S., Kim, Y. H., Mills, G. B., Hortobágyi, G. N., Stanbridge, E. J., & Lee, E. Y.-H. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5480 · Cited by 305 · see citing works

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

Rosell, R., Gatzemeier, U., Betticher, D. C., Keppler, U., Macha, H.-N., Pirker, R., Berthet, P., Breau, J. L., LIANES, P., Nicholson, M., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf332 · Cited by 299 · see citing works

Basal-like breast carcinomas: clinical outcome and response to chemotherapy

Banerjee, S. N., Reis-Filho, J. S., Ashley, S., Steele, D., Ashworth, A., Lakhani, S. R., & Smith, I. E. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.033043 · Cited by 289 · see citing works

Platinum-based chemotherapy in triple-negative breast cancer

Sirohi, B., Arnedos, M., Popat, S., Ashley, S. E., Nerurkar, A. Y., Walsh, G., Johnston, S. R. D., & Smith, I. E. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn395 · Cited by 220 · see citing works

BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis

Foulkes, W. D. (2006) · Familial Cancer · doi:10.1007/s10689-005-2832-5 · Cited by 135 · see citing works

Olive oil, other seasoning fats, and the risk of colorectal carcinoma

Braga, C., Vecchia, C. L., Franceschi, S., Negri, E., Parpinel, M. T., Decarli, A., Giacosa, A., & Trichopoulos, D. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980201)82:3 · Cited by 126 · see citing works

Triple Receptor–Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes

Dawood, S. S., Broglio, K. R., Kau, S., Green, M. C., Giordano, S. H., Meric‐Bernstam, F., Buchholz, T. A., Albarracin, C. T., Yang, W. T., Hennessy, B. T., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9952 · Cited by 112 · see citing works

Preoperative weekly cisplatin–epirubicin–paclitaxel with G-CSF support in triple-negative large operable breast cancer

Frasci, G., Comella, P., Rinaldo, M., Iodice, G., Bonito, M. D., D’Aiuto, M., Petrillo, A., Lastoria, S., Siani, C., Comella, G., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn748 · Cited by 91 · see citing works

Individual patient data meta-analyses

Clarke, M. J. (2004) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2004.10.011 · Cited by 65 · see citing works

Basal-like subtype and BRCA1 dysfunction in breast cancers

Miyoshi, Y., Murase, K., & Oh, K. (2008) · International Journal of Clinical Oncology · doi:10.1007/s10147-008-0831-x · Cited by 38 · see citing works

Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than withP53 gene mutation

Koga, T., Hashimoto, S., Sugio, K., Yoshino, I., Nakagawa, K., Yonemitsu, Y., Sugimachi, K., & Sueishi, K. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010720)95:4 · Cited by 34 · see citing works

“Targeting” Triple-Negative Breast Cancer: The Lessons Learned From BRCA1-Associated Breast Cancers

Nanda, R. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.01.007 · Cited by 23 · see citing works

HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy

Falo, C., Moreno, A., Varela, M., Lloveras, B., Figueras, A., & Escobedo, A. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-006-0176-7 · Cited by 20 · see citing works

A Phase II Trial of a Neoadjuvant Platinum Regimen for Locally Advanced Breast Cancer: Pathologic Response, Long-Term Follow-up, and Correlation With Biomarkers

Yerushalmi, R., Hayes, M. M., Gelmon, K. A., Chia, S., Bajdik, C. D., Norris, B. D., Speers, C. H., Hassell, P., O’Reilly, S. E., Allan, S. J., et al. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.n.027 · Cited by 15 · see citing works

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

von Minckwitz, G., Schneeweiß, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,025 · see citing works

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C., Tolaney, S. M., Kuzma, C. S., Pluard, T., Somlo, G., Port, E. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,017 · see citing works

Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis

Spring, L. M., Fell, G. G., Arfè, A., Sharma, C., Greenup, R. A., Reynolds, K. L., Smith, B. L., Alexander, B. M., Moy, B., Isakoff, S. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3492 · Cited by 954 · see citing works

Biology and Management of Patients With Triple-Negative Breast Cancer

Sharma, P. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0067 · Cited by 294 · see citing works

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial

Hu, X., Zhang, J., Xu, B.-H., Cai, L., Ragaz, J., Wang, Z., Wang, B.-Y., Teng, Y., Tong, Z., Pan, Y.-Y., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70064-1 · Cited by 287 · see citing works

Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis

Huang, M., O’Shaughnessy, J., Zhao, J., Haiderali, A., Cortés, J., Ramsey, S. D., Briggs, A. H., Hu, P. H., Karantza, V., Aktan, G., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1792 · Cited by 171 · see citing works

Triple-Negative Breast Cancer

Chaudhary, L. N., Wilkinson, K. H., & Kong, A. L. (2017) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.08.004 · Cited by 153 · see citing works

Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51

Lee, J. O., Kang, M. J., Byun, W. S., Kim, S. A., Seo, I. H., Han, J. A., Moon, J. W., Kim, J. H., Kim, S. J., Lee, E. J., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1204-2 · Cited by 141 · see citing works

The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis

Petrelli, F., Coinu, A., Borgonovo, K., Cabiddu, M., Ghilardi, M., Lonati, V., & Barni, S. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2876-z · Cited by 133 · see citing works

The History of Early Breast Cancer Treatment

Ben-Dror, J., Shalamov, M. M., & Sonnenblick, A. (2022) · Genes · doi:10.3390/genes13060960 · Cited by 138 · see citing works

Therapies for triple negative breast cancer

Andreopoulou, E., Schweber, S. J., Sparano, J. A., & McDaid, H. M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1032246 · Cited by 100 · see citing works

Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damagePreprint

Hill, S. J., Rolland, T., Adelmant, G., Xia, X., Owen, M., Dricot, A., Zack, T. I., Sahni, N., Jacob, Y., Hao, T., et al. (2014) · Genes & Development · doi:10.1101/gad.241620.114 · Cited by 97 · see citing works

Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?

Wang-Lopez, Q., Chalabi, N., Abrial, C., Radosevic‐Robin, N., Durando, X., Mouret‐Reynier, M., Benmammar, K.-E., Kullab, S. A., Bahadoor, M. R. K., Chollet, P. J. M., et al. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.02.011 · Cited by 95 · see citing works

Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial

Zhang, P., Yin, Y., Mo, H., Zhang, B., Wang, X., Li, Q., Yuan, P., Wang, J., Zheng, S., Cai, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10607 · Cited by 91 · see citing works

Lipid Nanocarriers of a Lipid-Conjugated Estrogenic Derivative Inhibit Tumor Growth and Enhance Cisplatin Activity against Triple-Negative Breast Cancer: Pharmacokinetic and Efficacy Evaluation

Andey, T. A., Godeshala, S., Marepally, S. K., Patel, A. R., Banerjee‬‬‬‬‬‬‬‬‬, R., & Singh, M. S. (2015) · Molecular Pharmaceutics · doi:10.1021/mp5008629 · Cited by 77 · see citing works

Imaging Updates to Breast Cancer Lymph Node Management

Chung, H. L., Le‐Petross, H. T., & Leung, J. W. T. (2021) · Radiographics · doi:10.1148/rg.2021210053 · Cited by 76 · see citing works

Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going

Omarini, C., Guaitoli, G., Pipitone, S., Moscetti, L. I., Cortesi, L., Cascinu, S., & Piacentini, F. (2018) · Cancer Management and Research · doi:10.2147/cmar.s146658 · Cited by 75 · see citing works

Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer

Zhang, J., Wang, Z., Hu, X., Wang, B., Wang, L., Yang, W., Liu, Y., Liu, G., Di, G., Hu, Z., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28966 · Cited by 75 · see citing works

Prognostic and predictive value of Ki-67 in triple-negative breast cancer

Wang, W., Wu, J., Zhang, P., Fei, X., Zong, Y., Chen, X., Huang, O., He, J., Chen, W., Li, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9075 · Cited by 57 · see citing works

Cisplatin (CDDP) triggers cell death of MCF-7 cells following disruption of intracellular calcium ([Ca2+]i) homeostasis

Al-Taweel, N., Varghese, E., Florea, A.-M., & Büsselberg, D. (2014) · The Journal of Toxicological Sciences · doi:10.2131/jts.39.765 · Cited by 52 · see citing works

Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes

Walsh, E. M., Keane, M., Wink, D. A., Callagy, G. M., & Glynn, S. A. (2016) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2017021307 · Cited by 52 · see citing works

Neoadjuvant chemotherapy in triple‐negative breast cancer: A multicentric retrospective observational study in real‐life setting

Gamucci, T., Pizzuti, L., Sperduti, I., Mentuccia, L., Vaccaro, A., Moscetti, L. I., Marchetti, P., Carbognin, L., Michelotti, A., Iezzi, L., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26103 · Cited by 48 · see citing works

A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

Wu, X., Tang, P., Li, S., Wang, S., Liang, Y., Zhong, L., Ren, L., Zhang, T., & Zhang, Y. (2018) · Nature Communications · doi:10.1038/s41467-018-03210-2 · Cited by 47 · see citing works

Aetio-pathogenesis of breast cancer

Abdulkareem, I. H. (2013) · Nigerian Medical Journal · doi:10.4103/0300-1652.126284 · Cited by 46 · see citing works

BRCA1 Pathway Function in Basal-Like Breast Cancer Cells

Hill, S. J., Clark, A. P., Silver, D. P., & Livingston, D. M. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01646-13 · Cited by 44 · see citing works

Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis

Pathak, N., Sharma, A., Elavarasi, A., Sankar, J., Deo, S. V. S., Sharma, D. N., Mathur, S. R., Kumar, S., Prasad, C. P., Kumar, A., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.04.006 · Cited by 44 · see citing works

Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model

Tonsing-Carter, E., Bailey, B. J., Saadatzadeh, M. R., Ding, J., Wang, H., Sinn, A. L., Peterman, K. M., Spragins, T. K., Silver, J. M., Sprouse, A. A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0237 · Cited by 42 · see citing works

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy

Zhang, J., Fan, M., Xie, J., Wang, Z., Wang, B., Zhang, S., Wang, L., Cao, J., Tao, Z., Li, T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5654 · Cited by 40 · see citing works

Influence of MiR-451 on Drug Resistances of Paclitaxel-Resistant Breast Cancer Cell Line

Gu, X., Li, J., Guo, J., Li, P., & Zhang, W. (2015) · Medical Science Monitor · doi:10.12659/msm.894475 · Cited by 36 · see citing works

Both Carboplatin and Bevacizumab Improve Pathological Complete Remission Rate in Neoadjuvant Treatment of Triple Negative Breast Cancer: A Meta-Analysis

Chen, X., Yuan, Y., Garfield, D. H., Wu, J., Huang, O., & Shen, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108405 · Cited by 35 · see citing works

Assessing the Role of Platinum Agents in Aggressive Breast Cancers

Sikov, W. M. (2015) · Current Oncology Reports · doi:10.1007/s11912-014-0428-7 · Cited by 35 · see citing works

Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer

Gao, M., Wang, T., Ji, L., Bai, S., Tian, L., & Song, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00366 · Cited by 35 · see citing works

Platinum-based chemotherapy in triple-negative breast cancer

Guan, X., Ma, F., Fan, Y., Zhu, W., Hong, R., & Xu, B. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000260 · Cited by 35 · see citing works

Platinum-based chemotherapy in triple-negative advanced breast cancer

Villarreal-Garza, C., Khalaf, D., Bouganim, N., Clemons, M., Peña-Curiel, O., Baez-Revueltas, B., Kiss, A., Kassam, F., Enright, K., Verma, S., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3033-4 · Cited by 33 · see citing works

Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis

Saleh, R., Nadler, M. B., Desnoyers, A., Meti, N., Fazelzad, R., & Amir, E. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102283 · Cited by 30 · see citing works

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer

Huang, L., Liu, Q., Chen, S., & Shao, Z. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s145934 · Cited by 28 · see citing works

The use of oncolytic virotherapy in the neoadjuvant setting

Thomas, R. J., & Bartee, E. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004462 · Cited by 27 · see citing works

Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US

Chen, J., Han, M., Liu, A., & Shi, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.734594 · Cited by 27 · see citing works

Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model

Rui, M., Shi, F., Shang, Y., Meng, R., & Li, H. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01418-7 · Cited by 25 · see citing works

Pathologic complete response and breast cancer survival post-neoadjuvant chemotherapy: A systematic review and meta-analysis of real-world data

Antonini, M., Mattar, A. P. L., Pereira, T. P., Oliveira, L. L., Teixeira, M. D., Amorim, A. G., Ferraro, O., de Oliveira, L. C., Ramos, M. D. N. M., Cavalcante, F. P., et al. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e43069 · Cited by 24 · see citing works

Oncolytic viruses as anticancer agents: clinical progress and remaining challenges

Appleton, E. S., Chiocca, E. A., Ungerechts, G., Melcher, A. A., & Vile, R. G. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01206-1 · Cited by 24 · see citing works

Advances in Small-Molecule Drug Discovery for Triple-Negative Breast Cancer

Fosu-Mensah, N., Peris, M. S., Weeks, H. P., Cai, J., & Westwell, A. D. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.129 · Cited by 23 · see citing works

Updates in Neoadjuvant Therapy for Triple Negative Breast Cancer

Tufano, A. M., Teplinsky, E., & Landry, C. A. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.07.001 · Cited by 22 · see citing works

Neoadjuvant, Anthracycline-Free Chemotherapy with Carboplatin and Docetaxel in Triple-Negative, Early-Stage Breast Cancer: A Multicentric Analysis of Feasibility and Rates of Pathologic Complete Response

Kern, P., Kalisch, A., Kolberg, H., Kimmig, R., Otterbach, F., von Minckwitz, G., Sikov, W. M., Pott, D., & Kurbacher, C. M. (2013) · Chemotherapy · doi:10.1159/000362756 · Cited by 21 · see citing works

A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin–docetaxel with or without trastuzumab in locally advanced breast cancer

Al‐Tweigeri, T., Alsayed, A., Alawadi, S., Ibrahim, M. F. K., Ashour, W. M., Jaafar, H., Abulkhair, O. A. M., Alabdulkarim, H. A., Khalid, H., & Ajarim, D. S. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2906-5 · Cited by 18 · see citing works

Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer

Yardley, D. A., Shipley, D. L., Peacock, N. W., Shastry, M., Midha, R., Priego, V. M., & Hainsworth, J. D. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3482-4 · Cited by 17 · see citing works

A Meta-Analysis of Platinum-Based Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

Wang, D., Feng, J., & Xu, B. (2019) · Future Oncology · doi:10.2217/fon-2019-0165 · Cited by 17 · see citing works

A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer

Jin, X., Jiang, Y., Chen, S., Yu, K., Ma, D., Sun, W., Shao, Z.-M., & Di, G. (2016) · BMC Cancer · doi:10.1186/s12885-016-2652-z · Cited by 17 · see citing works

Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a 5-year follow-up of a randomized, open-label, phase II trial

Yan, W., Wu, X., Wang, S., He, C., Zhong, L., Tang, P., Ren, L., Zhang, T., Qi, X., & Zhang, Y. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221107111 · Cited by 16 · see citing works

Preoperative Systemic Therapy for Breast Cancer

Kodali, A., & Gadi, V. K. (2022) · Surgical Clinics of North America · doi:10.1016/j.suc.2022.08.017 · Cited by 15 · see citing works

Pathological complete response following cisplatin or carboplatin‑based neoadjuvant chemotherapy for triple‑negative breast cancer: A systematic review and meta‑analysis

Vidra, R., Nemeș, A., Vidrean, A., Pintea, S., Tintari, S., Deac, A. L., & Ciuleanu, T. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.11014 · Cited by 15 · see citing works

ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy

Palomba, G., Atzori, F., Budroni, M., Ombra, M. N., Cossu, A., Sini, M. C., Pusceddu, V., Massidda, B., Frau, B., Notari, F., et al. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0272-4 · Cited by 14 · see citing works

Targeted Chinese Medicine Delivery by A New Family of Biodegradable Pseudo-Protein Nanoparticles for Treating Triple-Negative Breast Cancer: In Vitro and In Vivo Study

Kwan, H. Y., Xu, Q., Gong, R., Bian, Z., & Chu, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.600298 · Cited by 13 · see citing works

Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel

Gu, X. J., Jia, S., Wei, W., & Zhang, W. (2015) · Tumor Biology · doi:10.1007/s13277-015-3221-9 · Cited by 13 · see citing works

A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis

Pattarawat, P., Hunt, J. T., Poloway, J., Archibald, C. J., & Wang, H. R. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04298-y · Cited by 11 · see citing works

Anthracycline-Free Neoadjuvant Chemotherapy Ensures Higher Rates of Pathologic Complete Response in Breast Cancer

Iuliis, F. D., Salerno, G., Corvino, R., D’Aniello, D., Cefalì, K., Taglieri, L., Lanza, R., & Scarpa, S. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.06.010 · Cited by 11 · see citing works

Impact de la réponse histologique complète à la chimiothérapie néo-adjuvante pour cancer du sein selon le sous-type moléculaire

Cirier, J., Body, G., Jourdan, M. L., Bédouet, L., Fleurier, C., Pilloy, J., Arbion, F., & Ouldamer, L. (2017) · Gynécologie Obstétrique Fertilité & Sénologie · doi:10.1016/j.gofs.2017.08.002 · Cited by 11 · see citing works

Erianin inhibits the progression of triple-negative breast cancer by suppressing SRC-mediated cholesterol metabolism

Li, M., Kang, S., Deng, X., Li, H., Zhao, Y., Tang, W., & Sheng, M. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03332-2 · Cited by 9 · see citing works

Nanoscale Coordination Polymers for Combined Chemotherapy and Photodynamic Therapy of Metastatic Cancer

Li, Y., Han, W., He, C., Jiang, X., Fan, Y., & Lin, W. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00362 · Cited by 8 · see citing works

Characterization of PI (breast cancer cell special peptide) in MDA-MB-231 breast cancer cells and its potential therapeutic applications

Gao, C., Hong, M. H., GENG, J., Zhou, H., & Dong, J. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3140 · Cited by 7 · see citing works

Impact of Expression Levels of Platinum-uptake Transporters Copper Transporter 1 and Organic Cation Transporter 2 on Resistance to Anthracycline/Taxane-based Chemotherapy in Triple-negative Breast Cancer

Takeda, R., Naka, A., Ogane, N., Kameda, Y., Kawachi, K., Shimizu, S., & Kamoshida, S. (2015) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s27534 · Cited by 6 · see citing works

Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial

Jiao, D., Qiao, J., Sun, X., Wang, C., Lu, Z., Zhang, C., Li, L., Yan, M., Feng, Y., Zhou, Y., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0289 · Cited by 5 · see citing works

Pathological response and clinical outcomes in operable triple-negative breast cancer with cisplatin added to standard neoadjuvant chemotherapy

Singh, A., Georgy, J. T., John, A. O., Joel, A., Thumaty, D. B., Rebekah, G. J., Sigamani, E., Chandramohan, J., Manipadam, M. T., Cherian, A. J., et al. (2021) · Klinicka onkologie · doi:10.48095/ccko202149 · Cited by 5 · see citing works

The Current Role of Neoadjuvant Chemotherapy in the Management of HER2-Positive, Triple-Negative, and Micropapillary Breast Cancer: A Narrative Review

Wankhade, D., Gharde, P., & Dutta, S. (2023) · Cureus · doi:10.7759/cureus.49742 · Cited by 4 · see citing works

Mechanism of Erianin anti-triple negative breast cancer based on transcriptomics methods and network pharmacology

Li, M., Zhao, Y., Li, H., Kang, S., Deng, X., & Sheng, M. (2024) · Aging · doi:10.18632/aging.205516 · Cited by 3 · see citing works

Dynamic ultrasound-based modeling predictive of response to neoadjuvant chemotherapy in patients with early breast cancer

Wang, X., Zhang, Y., Yang, M., Wu, N., Wang, S., Chen, H., Zhou, T., Zhang, Y., Wang, X., Jin, Z., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-80409-y · Cited by 3 · see citing works

La connaissance du statut de BRCA1 devrait-elle avoir un impact sur le choix d’un cytotoxique dans le cancer du sein ? Revue de la littérature

Clergue, O., Jones, N. B., Sévenet, N., Quénel-Tueux, N., & Debled, M. (2015) · Bulletin du Cancer · doi:10.1016/j.bulcan.2015.01.010 · Cited by 3 · see citing works

Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine as First-Line Therapy for Metastatic Triple Negative Breast Cancer

Mustafa, S. H. S., Zamzam, M. L., Mohsen, S. E.-S. A., & Hassanen, E. M. (2019) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2019.28871 · Cited by 3 · see citing works

Bayesian decision making in confirmatory early-stage breast cancer trial

Gu, E., Zhou, X., & Zhao, J. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106280 · Cited by 2 · see citing works

Carvacrol Promotes Cisplatin-induced Apoptosis of Triple-negative Breast Cancer Through TRPM7 ChannelsPreprint

Li, J., Ye, H., Wang, J., Qin, J., & Chen, L. (2021) · Research Square · doi:10.21203/rs.3.rs-291089/v1 · Cited by 2 · see citing works

Can we counterbalance restricted access to innovation through specialized breast cancer care? The REAL-NOTE study

de Matos, L. V., Debiasi, M., Padrão, T. G., Sousa, B., Louro, T., & Cardoso, F. (2024) · The Breast · doi:10.1016/j.breast.2024.103793 · Cited by 1 · see citing works

My burning issues in the neoadjuvant treatment for breast cancer

Bergen, E. S., & Bartsch, R. (2017) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-017-0378-5 · Cited by 1 · see citing works

Anti-cancer Effect of Recombinant PI-Laterosporulin10 as a Novel Bacteriocin with Selective Cytotoxicity on Triple Negative Breast Cancer Cells

Rafizadeh, B., Reiisi, S., Saffar, B., Taheri, F., & Farhadian, S. (2022) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-022-10453-7 · Cited by 1 · see citing works

Dose-Dense Docetaxel-Cyclophosphamide and Epirubicin-Cisplatin(ddDCEP): Analysis of an Alternative Platinum-Containing Regimen in 116 Patients with Early Triple Negative Breast Cancer

Singh, A., Georgy, J. T., Joel, A., Thumaty, D. B., John, A. O., Ramnath, N., George, T. K., Sharma, P., Patole, S., Rebekah, G. J., et al. (2023) · Cancer Investigation · doi:10.1080/07357907.2023.2278048 · Cited by 1 · see citing works

Modulation of the Mdm2 signaling axis sensitizes triple-negative breast cancer cells to carboplatin

Tonsing-Carter, E. Y. (2014) · ProQuest Demo Repository · doi:10.7912/c2/308

PLATINUM BASED VERSUS ANTHRACYCLIN BASED NEOADJUVANT CHEMOTHERAPY IN NONMETASTATIC TRIPLE NEGATIVE BREAST CANCER (TNBC) PATIENTS

Adel, A., Abdel-Aziz, H., Diab, D., Gaddalla, M., & Mostafa, M. Y. (2022) · Ain Shams Medical Journal · doi:10.21608/asmj.2022.270221

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients

-, O. P. M., -, S. K., -, A. P. T. K., & -, A. S. (2023) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2023.v05i02.1995

Data from Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis

Huang, M., O’Shaughnessy, J., Zhao, J., Haiderali, A., Cortés, J., Ramsey, S. D., Briggs, A. H., Hu, P., Karantza, V., Aktan, G., et al. (2023) · doi:10.1158/0008-5472.c.6512472

Data from Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis

Huang, M., O’Shaughnessy, J., Zhao, J., Haiderali, A., Cortés, J., Ramsey, S. D., Briggs, A. H., Hu, P., Karantza, V., Aktan, G., et al. (2023) · doi:10.1158/0008-5472.c.6512472.v1

Updates in the Management of Triple Negative BC: Review article

Abdelshakour, E. I., Hassan, E. E., & Ali, E. M. (2023) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2023.307718

Neoadjuvant docetaxel plus cisplatin versus docetaxel plus doxorubicin and cyclophosphamide in early-stage triple-negative breast cancer (HELEN-001): results from a multicenter, randomized controlled, open-label phase II trialPreprint

Liu, Z., Jiao, D., Qiao, J., Wang, C., Sun, X., Lu, Z., Zhang, C., Li, L., Yan, M., Feng, Y., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4078861/v1

Assessment of Clinicopathological Response to Neoadjuvant Chemotherapy in Patients Diagnosed With Locally Advanced Breast Carcinoma

Balji, A., Ramchandani, R., Ramchandani, S., Chowhan, A. K., Agarwal, A., & Kashyap, Y. (2025) · Cureus · doi:10.7759/cureus.82057

Adjuvante und neoadjuvante Chemotherapie des Mammakarzinoms

Untch, M., & Thomssen, C. (2015) · Der Onkologe · doi:10.1007/s00761-014-2839-3

Neoadjuvant platinum-based chemotherapy (CT) for triple-negative locally advanced breast cancer (LABC): Retrospective analysis of 125 patients

Leone, J. P., Guardiola, V., Venkatraman, A., Pegram, M. D., Welsh, C. F., Silva, O., Larrieux, R., Franchesci, D., Gómez, C., & Hurley, J. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.625 · Cited by 22 · see citing works

Survival of patients with locally advanced triple-negative breast cancer after neoadjuvant platinum-containing chemotherapy: Experience of a single institute.

Ibrahim, E. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.27_suppl.274

Neoadjuvant Platinum Based Chemotherapy in Triple Negative Breast Cancer-Preliminary Experience from A Tertiary Cancer Centre.

Shenoy, P. K., Jones, J., Vinin, N. V., Avaronnan, M., Geetha, M., & Rathi, P. (2021) · International Journal of Pharma and Bio Sciences · doi:10.22376/ijpbs.2021.12.2.b71-77 · Cited by 1 · see citing works

The Role of Platinum Based Chemotherapy in Neoadjuvant Treatment of Locally Advanced Triple Negative Breast cancer

Abdelaziz, H. M., Diab, D., Adel, A. M., Mostafa, M. Y., & Gaddalla, M. (2020) · QJM · doi:10.1093/qjmed/hcaa057.009

Clinicopathological Predictors of Pathologic Complete Response in Triple-Negative Breast Cancer: Impact of Platinum-Based Neoadjuvant Chemotherapy

Özyurt, N., & Turhan, A. (2026) · Medical Records · doi:10.37990/medr.1828536